FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint
Executive Summary
Amgen sees the approval as a platform to expand blinatumomab into other hematologic malignancies using similar approaches.
You may also be interested in...
Advanced Antibodies Will Revolutionize The Future Of IO
Immuno-oncology is a key area for biological drug development and activity has exploded over the past decade. Today, IO therapies represent a third of the biologics pipeline, and antibody development remains the focus.
Endpoint Milestone In AML: Kronos’ Entospletinib Trial Will Rely On Residual Disease
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.
Amgen, Adaptive Partner In COVID-19 Neutralizing Antibody R&D Effort
The companies are combining their technologies to seek neutralizing antibody therapeutics that could prevent or treat COVID-19, building on their previous partnership in monitoring minimal residual disease in blood cancers.